Top Core and Group Health Stories
New treatments for people with a rare form of heart failure are in the pipeline
By Andy SzczotkaFor employers' health plans, the new ATTR-CM specialty drugs could cost $500,000 per participant treated.
News, insight, and analysis from industry experts to help benefits brokers, consultants and advisors make their way through the tumultuous reformed health care marketplace. Content will help them grow their practices by focusing on a wide range of products, discussing new sales and marketing strategies and highlighting innovative and disruptive brokers who are forging a new path in today's benefits marketplace.
For employers' health plans, the new ATTR-CM specialty drugs could cost $500,000 per participant treated.